Study on Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer
Part of Cancer, Kidney & urinary clinical trials.
This study looks at how well men with prostate cancer that has spread and is still hormone-sensitive stick to taking the drug apalutamide. It aims to understand real-world use and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are male and 18 years or older.
- You have been diagnosed with prostate cancer that has spread to other parts of your body.
- Your prostate cancer is still hormone-sensitive (it responds to hormone therapy).
- You and your doctor have decided to start treatment with apalutamide and hormone therapy before joining the study.
- You agree to fill out questionnaires about your medication use and quality of life.
- You have not taken apalutamide or similar drugs (like abiraterone or enzalutamide) or chemotherapy for this stage of cancer before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a chemotherapy drug (docetaxel) to your current treatment (apalutamide) can help control prostate cancer that has spread and hasn't responded as well as hoped to apalutamide alone.
This study looks at how well darolutamide and similar drugs work for men whose prostate cancer has just spread to other parts of the body. It aims to understand real-world outcomes in urology clinics.
This trial tests a new way to predict how well hormone therapy combined with newer drugs works for men with prostate cancer that has spread. It uses advanced tissue analysis to help tailor treatment.
This study tests an experimental drug called ASP5541 for men with metastatic prostate cancer (either hormone-sensitive or castration-resistant). It aims to see if the drug can slow cancer growth and improve outcomes when added to standard hormone therapy.
This trial studies whether adding apalutamide to standard hormone therapy (ADT) improves outcomes for men with metastatic hormone-sensitive prostate cancer. Some people may also receive local treatments (like surgery or radiotherapy) to control the prostate and nearby areas.
This study tests different ways of giving hormone therapy to find the right dose for men with prostate cancer that has spread. It aims to help manage the disease while limiting side effects.
Hear when a new Prostatic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.